BioCardia (NASDAQ: BCDA) warned on $1 rule, listing at risk
Rhea-AI Filing Summary
BioCardia, Inc. (BCDA) reports that Nasdaq has notified the company that its common stock has failed to meet the $1.00 per share Minimum Bid Price Requirement for the last 30 consecutive business days, putting its Nasdaq Capital Market listing at risk under Nasdaq Listing Rule 5550(a)(2).
BioCardia has an initial 180-day grace period, until February 16, 2027, to regain compliance by having a closing bid of at least $1.00 for at least ten consecutive business days. The notice does not immediately affect trading. If still noncompliant, BioCardia may seek an additional 180 days, potentially including a reverse stock split, and could appeal any delisting determination.
Positive
- None.
Negative
- Nasdaq has notified BioCardia that its stock has traded below the $1.00 minimum bid for 30 consecutive business days, triggering a potential Nasdaq Capital Market delisting process if compliance is not regained by February 16, 2027 or any extended deadline.
Filing Explained
The second 180-day compliance period is not automatic: after
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum bid price requirement: $1.00 per share
Non-compliance trading period: 30 consecutive business days
Initial compliance period: 180 calendar days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Capital Market continued listing requirement under Listing Rule 5550(a)(2)
Non-compliance trading period
30 consecutive business days
Period during which BioCardia’s common stock closed below $1.00 per share
Initial compliance period
180 calendar days
Time granted to regain minimum bid price compliance, ending February 16, 2027
Initial compliance deadline
February 16, 2027
Date by which BioCardia must regain compliance with the Minimum Bid Price Requirement
Potential additional compliance period
180 calendar days
Additional period Nasdaq may grant if other listing standards and conditions are met
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), reverse stock split, forward-looking statements
4 terms
Minimum Bid Price Requirement market
"the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
reverse stock split financial
"by effecting a reverse stock split, if necessary"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
forward-looking statements regulatory
"contains “forward-looking statements” within the meaning of Section 21E"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
Why did BioCardia (BCDA) receive a Nasdaq non-compliance notice?
BioCardia received a Nasdaq notice because its common stock’s minimum bid price was below $1.00 per share for the last 30 consecutive business days, violating the Nasdaq Capital Market Minimum Bid Price Requirement under Listing Rule 5550(a)(2).
How long does BioCardia (BCDA) have to regain Nasdaq bid price compliance?
BioCardia has an initial 180 calendar days, until February 16, 2027, to regain compliance. Nasdaq will deem the company compliant if the closing bid price is at least $1.00 per share for a minimum of ten consecutive business days within this period.
Does the Nasdaq notice immediately affect trading in BioCardia (BCDA) stock?
No. The company states that the Nasdaq notice has no immediate effect on the listing or trading of its common stock on the Nasdaq Capital Market. The stock continues to trade while the company works to regain compliance.
Can BioCardia (BCDA) get more time beyond February 16, 2027 to fix its bid price?
Yes. If still noncompliant by February 16, 2027, BioCardia may qualify for an additional 180-day compliance period, if it meets all other initial Nasdaq Capital Market listing standards and notifies Nasdaq of its plan to cure, potentially via a reverse stock split.
What happens if BioCardia (BCDA) ultimately fails to regain Nasdaq compliance?
If BioCardia does not qualify for, or fails during, any additional compliance period, Nasdaq staff will notify the company that its common stock is subject to delisting. BioCardia would then be entitled to appeal the delisting determination to a Nasdaq hearings panel.
What actions might BioCardia (BCDA) take to regain bid price compliance?
BioCardia states it intends to actively monitor its closing bid price and may consider available options to regain compliance with the Minimum Bid Price Requirement, including potentially effecting a reverse stock split if necessary during a second compliance period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
